Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis. Truong, T. M., Pathak, G. N., Singal, A., Taranto, V., & Rao, B. K. The Annals of Pharmacotherapy, 58(4):416–427, April, 2024. doi abstract bibtex OBJECTIVE: The objective of this study was to review the safety and efficacy of deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor for moderate to severe plaque psoriasis. DATA SOURCES: Literature was reviewed from MEDLINE and Clinicaltrials.gov up to December 2022 using the terms "deucravacitinib" and "BMS-986165." STUDY SELECTION: Relevant articles in English relating to the pharmacodynamics, pharmacokinetics, efficacy, and safety of deucravacitinib were included. A total of 6 trial results were included. STUDY SELECTION AND DATA EXTRACTION: Deucravacitinib showed clinical efficacy across all the phase II and III clinical trials. Excluding the long-term extension study, there were 2248 subjects across all studies, with 63.2% of patients receiving deucravacitinib 6 mg daily. Of these subjects, the average proportion achieving a PASI 75 (a reduction of greater than 75% in the Psoriasis Area and Severity Index) at week 16 was 65.1%. Patients receiving deucravacitinib 6 mg once daily had a higher rate of achieving both PASI 75 response and a Static Physician's Global Assessment (sPGA) score of 0 or 1, compared with oral apremilast 30 mg twice daily. The safety profile of deucravacitinib includes mild adverse events (AEs), most commonly nasopharyngitis, with serious AEs reported ranging from 1.35% to 9.5%. RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE IN COMPARISON WITH EXISTING MEDICATIONS: While many available therapies for moderate to severe plaque psoriasis rely on an injectable dosage form or extensive monitoring, deucravacitinib can potentially reduce patient medication-related burden. This review summarizes the efficacy and safety of oral deucravacitinib for the treatment of severe plaque psoriasis. CONCLUSION: Deucravacitinib shows a consistent efficacy and safety profile as the first oral TYK2 inhibitor approved for adult patients with moderate to severe plaque psoriasis who are eligible for systemic therapy or phototherapy treatment.
@article{truong_deucravacitinib_2024,
title = {Deucravacitinib: {The} {First} {FDA}-{Approved} {Oral} {TYK2} {Inhibitor} for {Moderate} to {Severe} {Plaque} {Psoriasis}},
volume = {58},
issn = {1542-6270},
shorttitle = {Deucravacitinib},
doi = {10.1177/10600280231153863},
abstract = {OBJECTIVE: The objective of this study was to review the safety and efficacy of deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor for moderate to severe plaque psoriasis.
DATA SOURCES: Literature was reviewed from MEDLINE and Clinicaltrials.gov up to December 2022 using the terms "deucravacitinib" and "BMS-986165."
STUDY SELECTION: Relevant articles in English relating to the pharmacodynamics, pharmacokinetics, efficacy, and safety of deucravacitinib were included. A total of 6 trial results were included.
STUDY SELECTION AND DATA EXTRACTION: Deucravacitinib showed clinical efficacy across all the phase II and III clinical trials. Excluding the long-term extension study, there were 2248 subjects across all studies, with 63.2\% of patients receiving deucravacitinib 6 mg daily. Of these subjects, the average proportion achieving a PASI 75 (a reduction of greater than 75\% in the Psoriasis Area and Severity Index) at week 16 was 65.1\%. Patients receiving deucravacitinib 6 mg once daily had a higher rate of achieving both PASI 75 response and a Static Physician's Global Assessment (sPGA) score of 0 or 1, compared with oral apremilast 30 mg twice daily. The safety profile of deucravacitinib includes mild adverse events (AEs), most commonly nasopharyngitis, with serious AEs reported ranging from 1.35\% to 9.5\%.
RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE IN COMPARISON WITH EXISTING MEDICATIONS: While many available therapies for moderate to severe plaque psoriasis rely on an injectable dosage form or extensive monitoring, deucravacitinib can potentially reduce patient medication-related burden. This review summarizes the efficacy and safety of oral deucravacitinib for the treatment of severe plaque psoriasis.
CONCLUSION: Deucravacitinib shows a consistent efficacy and safety profile as the first oral TYK2 inhibitor approved for adult patients with moderate to severe plaque psoriasis who are eligible for systemic therapy or phototherapy treatment.},
language = {eng},
number = {4},
journal = {The Annals of Pharmacotherapy},
author = {Truong, Thu Minh and Pathak, Gaurav N. and Singal, Amit and Taranto, Viktoriia and Rao, Babar K.},
month = apr,
year = {2024},
pmid = {37341177},
keywords = {Adult, Double-Blind Method, Humans, JAK, Psoriasis, Severity of Illness Index, TYK2, TYK2 Kinase, Treatment Outcome, deucravacitinib, psoriasis},
pages = {416--427},
}
Downloads: 0
{"_id":"3us9suTmReT4o9HfB","bibbaseid":"truong-pathak-singal-taranto-rao-deucravacitinibthefirstfdaapprovedoraltyk2inhibitorformoderatetosevereplaquepsoriasis-2024","author_short":["Truong, T. M.","Pathak, G. N.","Singal, A.","Taranto, V.","Rao, B. K."],"bibdata":{"bibtype":"article","type":"article","title":"Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis","volume":"58","issn":"1542-6270","shorttitle":"Deucravacitinib","doi":"10.1177/10600280231153863","abstract":"OBJECTIVE: The objective of this study was to review the safety and efficacy of deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor for moderate to severe plaque psoriasis. DATA SOURCES: Literature was reviewed from MEDLINE and Clinicaltrials.gov up to December 2022 using the terms \"deucravacitinib\" and \"BMS-986165.\" STUDY SELECTION: Relevant articles in English relating to the pharmacodynamics, pharmacokinetics, efficacy, and safety of deucravacitinib were included. A total of 6 trial results were included. STUDY SELECTION AND DATA EXTRACTION: Deucravacitinib showed clinical efficacy across all the phase II and III clinical trials. Excluding the long-term extension study, there were 2248 subjects across all studies, with 63.2% of patients receiving deucravacitinib 6 mg daily. Of these subjects, the average proportion achieving a PASI 75 (a reduction of greater than 75% in the Psoriasis Area and Severity Index) at week 16 was 65.1%. Patients receiving deucravacitinib 6 mg once daily had a higher rate of achieving both PASI 75 response and a Static Physician's Global Assessment (sPGA) score of 0 or 1, compared with oral apremilast 30 mg twice daily. The safety profile of deucravacitinib includes mild adverse events (AEs), most commonly nasopharyngitis, with serious AEs reported ranging from 1.35% to 9.5%. RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE IN COMPARISON WITH EXISTING MEDICATIONS: While many available therapies for moderate to severe plaque psoriasis rely on an injectable dosage form or extensive monitoring, deucravacitinib can potentially reduce patient medication-related burden. This review summarizes the efficacy and safety of oral deucravacitinib for the treatment of severe plaque psoriasis. CONCLUSION: Deucravacitinib shows a consistent efficacy and safety profile as the first oral TYK2 inhibitor approved for adult patients with moderate to severe plaque psoriasis who are eligible for systemic therapy or phototherapy treatment.","language":"eng","number":"4","journal":"The Annals of Pharmacotherapy","author":[{"propositions":[],"lastnames":["Truong"],"firstnames":["Thu","Minh"],"suffixes":[]},{"propositions":[],"lastnames":["Pathak"],"firstnames":["Gaurav","N."],"suffixes":[]},{"propositions":[],"lastnames":["Singal"],"firstnames":["Amit"],"suffixes":[]},{"propositions":[],"lastnames":["Taranto"],"firstnames":["Viktoriia"],"suffixes":[]},{"propositions":[],"lastnames":["Rao"],"firstnames":["Babar","K."],"suffixes":[]}],"month":"April","year":"2024","pmid":"37341177","keywords":"Adult, Double-Blind Method, Humans, JAK, Psoriasis, Severity of Illness Index, TYK2, TYK2 Kinase, Treatment Outcome, deucravacitinib, psoriasis","pages":"416–427","bibtex":"@article{truong_deucravacitinib_2024,\n\ttitle = {Deucravacitinib: {The} {First} {FDA}-{Approved} {Oral} {TYK2} {Inhibitor} for {Moderate} to {Severe} {Plaque} {Psoriasis}},\n\tvolume = {58},\n\tissn = {1542-6270},\n\tshorttitle = {Deucravacitinib},\n\tdoi = {10.1177/10600280231153863},\n\tabstract = {OBJECTIVE: The objective of this study was to review the safety and efficacy of deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor for moderate to severe plaque psoriasis.\nDATA SOURCES: Literature was reviewed from MEDLINE and Clinicaltrials.gov up to December 2022 using the terms \"deucravacitinib\" and \"BMS-986165.\"\nSTUDY SELECTION: Relevant articles in English relating to the pharmacodynamics, pharmacokinetics, efficacy, and safety of deucravacitinib were included. A total of 6 trial results were included.\nSTUDY SELECTION AND DATA EXTRACTION: Deucravacitinib showed clinical efficacy across all the phase II and III clinical trials. Excluding the long-term extension study, there were 2248 subjects across all studies, with 63.2\\% of patients receiving deucravacitinib 6 mg daily. Of these subjects, the average proportion achieving a PASI 75 (a reduction of greater than 75\\% in the Psoriasis Area and Severity Index) at week 16 was 65.1\\%. Patients receiving deucravacitinib 6 mg once daily had a higher rate of achieving both PASI 75 response and a Static Physician's Global Assessment (sPGA) score of 0 or 1, compared with oral apremilast 30 mg twice daily. The safety profile of deucravacitinib includes mild adverse events (AEs), most commonly nasopharyngitis, with serious AEs reported ranging from 1.35\\% to 9.5\\%.\nRELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE IN COMPARISON WITH EXISTING MEDICATIONS: While many available therapies for moderate to severe plaque psoriasis rely on an injectable dosage form or extensive monitoring, deucravacitinib can potentially reduce patient medication-related burden. This review summarizes the efficacy and safety of oral deucravacitinib for the treatment of severe plaque psoriasis.\nCONCLUSION: Deucravacitinib shows a consistent efficacy and safety profile as the first oral TYK2 inhibitor approved for adult patients with moderate to severe plaque psoriasis who are eligible for systemic therapy or phototherapy treatment.},\n\tlanguage = {eng},\n\tnumber = {4},\n\tjournal = {The Annals of Pharmacotherapy},\n\tauthor = {Truong, Thu Minh and Pathak, Gaurav N. and Singal, Amit and Taranto, Viktoriia and Rao, Babar K.},\n\tmonth = apr,\n\tyear = {2024},\n\tpmid = {37341177},\n\tkeywords = {Adult, Double-Blind Method, Humans, JAK, Psoriasis, Severity of Illness Index, TYK2, TYK2 Kinase, Treatment Outcome, deucravacitinib, psoriasis},\n\tpages = {416--427},\n}\n\n\n\n","author_short":["Truong, T. M.","Pathak, G. N.","Singal, A.","Taranto, V.","Rao, B. K."],"key":"truong_deucravacitinib_2024","id":"truong_deucravacitinib_2024","bibbaseid":"truong-pathak-singal-taranto-rao-deucravacitinibthefirstfdaapprovedoraltyk2inhibitorformoderatetosevereplaquepsoriasis-2024","role":"author","urls":{},"keyword":["Adult","Double-Blind Method","Humans","JAK","Psoriasis","Severity of Illness Index","TYK2","TYK2 Kinase","Treatment Outcome","deucravacitinib","psoriasis"],"metadata":{"authorlinks":{}},"downloads":0},"bibtype":"article","biburl":"https://bibbase.org/zotero/raoresearch","dataSources":["aGgndugSyribdb2rd"],"keywords":["adult","double-blind method","humans","jak","psoriasis","severity of illness index","tyk2","tyk2 kinase","treatment outcome","deucravacitinib","psoriasis"],"search_terms":["deucravacitinib","first","fda","approved","oral","tyk2","inhibitor","moderate","severe","plaque","psoriasis","truong","pathak","singal","taranto","rao"],"title":"Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis","year":2024}